drugset / Trial / NCT03669835
The Sublimated Mare Milk Supplement in Hepatitis C
Completed
100 enrolled
Asfendiyarov Kazakh National Medical University
Eurasia Invest Ltd. · collabMinistry of Education and Science, Republic of Kazakhstan · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial studies the effect of sublimated mare milk supplement on patients with hepatitis C.
Timeline
- Start
- 2018-03-28
- Primary completion
- 2019-09-20
- Completion
- 2020-12-01
Publications
- Background Yershova IB. Features of intestinal micro-biocenosis in viral hepatitis and possibilities of its correction. Actual Infectology 2(3): 7-11, 2014
- Background Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008 May 29;453(7195):620-5. doi: 10.1038/nature07008.
- Background Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol. 2015 Feb 14;21(6):1691-702. doi: 10.3748/wjg.v21.i6.1691.
- Background Roderburg C, Luedde T. The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. Gut Microbes. 2014 Jul 1;5(4):441-5. doi: 10.4161/gmic.29599. Epub 2014 Jul 9.
- Background Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013 May;29(3):264-70. doi: 10.1097/MOG.0b013e32835ff948.
- Results Galina V. Fedotovskikh, Galija M. Shaymardanova, Manarbek B. Askarov, Maiya S.Zhumabaeva, Gulmira S. Dosataeva, Aigerim K. Smagulova, Sapargul Marat, Tatyana G. Ezhelenko. Efficiency of mesenchymal stem cell therapy in ulcerative colitis as assessed by the morphology of colon mucosa. J.Cellular Therapy and Transplantation.Vol.8,№2,2019,58-62.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mare milk | Unknown | 20 mg | — |
| Background | Daclatasvir | Small molecule | 60 mg | — |
| Background | Sofosbuvir | Small molecule | 400 mg | — |
| Background | lepidavir | Unknown | 90 mg | — |